Pharmacyclics I Janssen- COMMERCIAL

Sunnyvale,  CA 
United States
https://imbruvicahcp.com/

• Booth: 7134

WARNINGS AND PRECAUTIONS Hemorrhage, infections, cytopenias, cardiac arrhythmias, hypertension, second primary malignancies, tumor lysis syndrome, and embryo-fetal toxicity. ADVERSE REACTIONS The most common adverse reactions (≥30%) in patients with B-cell malignancies (MCL, CLL/SLL, WM and MZL) were thrombocytopenia (54.5%)*, diarrhea (43.8%), fatigue (39.1%), musculoskeletal pain (38.8%), neutropenia (38.6%)*, rash (35.8%), anemia (35.0%)*, and bruising (32.0%). *Treatment-emergent decreases (all grades) were based on laboratory measurements. Please see complete Important Safety Information in the video below. 1L=frontline, CLL=chronic lymphocytic leukemia, FCR=fludarabine, cyclophosphamide, and rituximab, SLL=small lymphocytic lymphoma, WM=Waldenström''s macroglobulinemia